On Friday, American Superconductor Corporation (NASDAQ:AMSC)’s shares declined -31.20% to $6.88.
American Superconductor Corporation (AMSC) declared that it has priced its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $6.00 per share.
The net proceeds to AMSC from this offering are predictable to be about $22.3 million, after deducting the underwriting discount and estimated offering expenses. AMSC anticipates closing the offering, subject to customary conditions, on or about April 29, 2015.
American Superconductor Corporation provides megawatt-scale solutions worldwide. The company operates in two segments, Wind and Grid. The Wind segment enables manufacturers to field wind turbines; provides a range of power electronics and software-based control systems, which are integrated and designed for optimized performance, efficiency, and grid compatibility; designs and develops onshore and offshore wind turbines; licenses its engineered wind turbine designs; and offers customer support services to wind turbine manufactures.
StemCells Inc (NASDAQ:STEM)’s shares dropped -25.60% to $0.610.
StemCells Inc (STEM) declared the pricing of an underwritten public offering of common stock and warrants with a public offering price of $0.70 for a fixed combination of one share of common stock and a warrant to purchase three-quarters of a share of common stock. The warrants have an exercise price of $0.85 per share, are exercisable right away, and will expire five years from the date of issuance.
The Company anticipates receiving gross proceeds of about $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company has also granted the underwriters a 30 day option to purchase up to an additional 5,357,250 shares of common stock and/or warrants to purchase up to an additional 4,017,938 shares of common stock to cover over-allotments, if any.
StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system.
At the end of Friday’s trade, Spectranetics Corp (NASDAQ:SPNC)‘s shares dipped -23.57 % to $26.52.
Spectranetics Corp (SPNC) stated financial results for the three months ended March 31, 2015. Highlights of the quarter, all contrast with the three months ended March 31, 2014 comprise:
- Revenue of $57.4 million, up 45% (47% constant currency1)
- Vascular Intervention revenue of $36.5 million grew 82% (84% constant currency)
- S. peripheral atherectomy revenue grew 16%
- AngioSculpt(R)revenue of $14.0 million achieved
- Lead Administration revenue of $16.4 million raised 14% (16% constant currency)
- S. revenue grew 53% to $48.6 million; International revenue grew 12% (24% constant currency) to $8.8 million
The Spectranetics Corporation, together with its auxiliaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads.
DeVry Education Group Inc (NYSE:DV), ended its Friday’s trading session with -18.29% loss, and closed at $30.70.
DeVry Education Group Inc (DV) stated academic, operational and financial results for its fiscal 2015 third quarter ended March 31, 2015. DeVry Group also stated enrollment results at Chamberlain College of Nursing, Carrington College, DeVry Brasil, and DeVry University with its Keller Graduate Schoola of Administration.
DeVry Education Group Inc. provides educational services worldwide. It operates in three segments: Medical and Healthcare; International and Professional Educational; and Business, Technology and Administration.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
